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Purpose or Objective: The prophylactic inguinal lymph-
nodes (LNs) radiotherapy (RT) is considered the standard 
treatment, however it implies more toxicity. Moreover, 
inguinal recurrence occurs in 0%-12% of T1-T2, and 19%-30% 
of T3-T4 patients (pts) who did not receive prophylactic 
inguinal RT. So, 70%-81% of T3-T4 pts are uselessly irradiated, 
and 0%-12% of T1-T2 pts should be treated. An improvement 
of staging is mandatory. Aim of this study is to evaluate the 
role of sentinel lymph-node biopsy (SLNB) in staging and 
treatment of pts with anal cancer.  
 
Material and Methods: Patients with squamous cell 
carcinoma of anal canal were staged with physical 
examination, endoscopy, chest and abdomen CT, pelvic MR, 
and simulation FDG-PET. Pts without gross inguinal LN 
metastasis were candidate for the lymphoscintigraphy with 
99mTC nanocolloid. The CTV included the GTV (primary 
tumour and positive LNs), mesorectum, internal and common 
iliac LNs. As the inguinal RT was considered standard, the 
radiation oncologists were left free to decide whether 
irradiate this region independently from the clinical stage 
and the SLNB histological results. PTV1 and PTV2 
corresponded to GTV and CTV, respectively, with a margin of 
0.5 cm. Prescribed dose was 50.4Gy in 28 F to the PTV2, and 
64.8Gy in 36 F, as sequential boost, to the PTV1. IMRT or 
Volumetric Modulated Arc Therapy (VMAT) were used. 
Concomitant chemotherapy consisted of 2 cycles of Mito-C 10 
mg/m2, and continuous infusion 5-FU 1000 mg/m2/day for 4 
consecutive days.  
 
Results: From 3/2008 to 2/2014, 48 consecutive pts were 
treated (T1=9, T2=15, T3=16, T4=8). PET was performed in 42 
out of the 48 pts, and 27 out of these 42 pts underwent 
lymphoscintigraphy. Pathologic inguinal uptake was shown in 
15/42 (36%) pts. Lymphoscigraphy was performed in 9 out of 
these 15 pts. Histological examination was performed in 8 pts 
(SLN not found in 1 pt) and confirmed inguinal metastasis in 
3/8 pts (37.5% ) but did not confirmed metastasis in 5 pts 
(62.5%). PET did not show pathologic uptake in 27/42 pts 
(64%). Lymphoscintigraphy was performed in 18 out of these 
27 pts: SLN was not found in 1 pt. Histological examination 
found metastasis in 2/17 (12%) and confirmed the absence of 
metastasis in 15 pts (88%). Thirty-one pts received 
prophylactic or curative RT to the groins, the “Groin group”, 
and 17 pts did not , the “No groin group”. All the 17 pts of 
the “No groin group” underwent SLNB procedure: 16 pts had 
SLNB histologically negative, 1 pt had lymphoscintigraphy 
negative (SLN not found ) and PET negative; two pts with PET 
positive in right inguinal LN but ipsilateral SLNB negative 
were not irradiated. No pt in both groups had inguinal relapse 
or progression. Of note, median follow up duration in the “No 
groin group” was 41 months (19.2-90.7 months). 
 
Conclusion: SLNB can further improve the PET based staging 
and select the “true negative” patients for which the inguinal 
LN irradiation could be avoided. 
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Purpose or Objective: to evaluate efficacy and tolerability 
of stereotactic ablative radiotherapy (SABR) in the treatment 
of patients with colorectal cancer with exclusive 
oligometastases to the lung. 
 
Material and Methods: we treated 62 lung metastases in 38 
patients with oligometastatic colorectal cancer. Inclusion 
criteria were: primary tumor controlled, ≤ 5 lung metastases, 
no other active sites of disease at the time of the SABR. Dose 
prescription was: 23Gy/1 fr per central lesion <30 cc (18 
lesions), 30Gy/1fr for peripheral metastases <30 cc (35 
lesions), 45Gy/3fr for peripheral lesion >30cc (9 lesions). 
Twenty patients had 1 metastasis (53%), 14 patients had 2 
metastases (37%)and 4 patients tree-to-four metastases 
(10%). Median BED was 120 Gy. OS, PFS, MFS, local control 
and toxicity were evaluated. 
 
Results: median follow-up was 24 months (ranged 3-76 mo). 
Median actuarial survival was 34 months (c.i. 20-47 months). 
Overall survival (OS) at 1-, 2- and 5-years was 80%, 50.7% and 
26.9% respectively. Complete response (CR) was achieved in 
22/62 lesions (35.4%). Median disease-free survival (DFS) was 
24 months (ranged 13-34 months). DFS at 1-, 2- and 5-years 
was 79.8% and 40.4% and 22%, respectively. Complete 
response (CR) was the only prognostic factor significantly 
correlated with OS, PFS and metastasis-free survival (MFS) 
(p= 0.001 in each case). Patients with CR had 1-,2- and 5-
years OS of 100%, 90.9% and 67.3%, while patients with 
partial response (PR) and stable disease (SD) had respectively 
69.2, 34.6% and 0% and 63.5% at 1 and 2-years and 15.9% at 
5-years. Acute G1-2 lung toxicity, according to the CTCAE-
V4.0, was 10%, G3 lung toxicity was 1.6%. Late G1-2 toxicity 
rate was 25%. No late G3 toxicity was found. 
 
Conclusion: SABR has a high rate of local control in the lung 
metastasis from colorectal cancer and also affect survival. CR 
statistically correlated with OS, PFS and MFS, even at long-
term. There is a need of prospective trials to confirm these 
data and to identify the right selection criteria and the best 
timing with systemic therapies. 
 
Poster: Clinical track: Gynaecological (endometrium, 
cervix, vagina, vulva)  
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Purpose or Objective: To determine the effect of the time 
interval between external beam radiotherapy (EBRT) and 
hyperthermia (HT) treatments on locoregional recurrence and 
overall survival of patients with cervical cancer. 
 
Material and Methods: This retrospective study included 59 
women with locally advanced (stage IB2-IVA) cervical cancer, 
all treated with radiotherapy and HT. Additional treatment 
with chemotherapy was reason for exclusion. 
Patients received four to five weekly HT treatments 
concurrent with 23-28 fractions (1.8-2.0 Gy) EBRT and a 
brachytherapy boost (20-24Gy). On HT treatment days, HT 
was given after EBRT. The mean time interval between the 
EBRT and HT treatments that were delivered on the same day 
was used to characterize the typical time interval for that 
patient. The median thereof (79.2 minutes) was used to split 
the cohort in a ‘short’ and ‘long’ time-interval group. Median 
time intervals were 65.8 minutes (range 33.8-79.2) and 91.7 
minutes (range 80.0-125.2) for the short and long time-
interval group, respectively.  
Locoregional recurrence and overall survival were estimated 
using Kaplan-Meier analysis, and compared by a log-rank test. 
To correct for any potential confounding factors, a stepwise 
Cox regression analysis using backward elimination was used 
with time-interval group, age, FIGO stage, number of HT 
treatments, tumour temperature during HT treatment (T90), 
lymph node status and smoking as covariates. 
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Results: Locoregional recurrence was significantly lower in 
the short time-interval group (Fig. 1). Recurrence rate at 2 
years was 11% (95%CI 3-36%) in the short time-interval group 
compared to 49% (95%CI 30-73%) in the long time-interval 
group. The stepwise Cox regression identified time-interval 
(a short interval is better), T90 (higher temperatures are 
beneficial) and age (younger age is unfavourable) as 
significant prognostic factors, and shows a favourable trend 
for lower FIGO stage (Table 1). 
Overall survival was also significantly better in the short 
time-interval group (Fig. 1). Overall survival at 2 years was 
60% (95%CI 39-75%) in the short group compared to 39% 
(95%CI 21-56%) in the long time-interval group. The stepwise 
Cox regression identifies a short time-interval and higher T90 
as significant factors for a favourable outcome (Table 1). 
 
 
 
Fig. 1. Kaplan-Meier curves for locoregional recurrence (left) 
and overall survival (right) after EBRT and HT for advanced 
cervical cancer, grouped by time-interval between EBRT and 
HT. 
Table 1 Results of the Cox multivariable analysis of 
locoregional recurrence and survival after radiotherapy and 
hyperthermia for advanced cervical cancer. 
 
 
 
Conclusion: A short time interval between EBRT and HT 
results in a significantly lower recurrence and better overall 
survival for locally advanced cervical cancer patients. 
Furthermore, a higher tumour temperature during HT is 
associated with lower locoregional recurrence and better 
overall survival, stressing the importance of HT quality 
assurance. 
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Purpose or Objective: To define the recommended dose in 
high-intermediate risk endometrial cancer (HIR-EC) patients 
postoperatively irradiated by simultaneous integrated boost 
volumetric modulated arc therapy (SIB-VMAT). 
 
Material and Methods: A radiation dose of 45 Gy over 5 
weeks, 1.8 Gy/fraction, was delivered to the vagina and the 
lymphatic drainage (planning target volume, PTV2). Radiation 
dose was escalated to the upper two thirds of vagina (PTV1) 
with the SIB-VMAT strategy, after 1 year follow up of the first 
15 patients. Two dose levels were planned: Level 1 (PTV2: 
45/1.8 Gy; PTV1: 55/2.2 Gy), and Level 2 (PTV2: 45/1.8 Gy; 
PTV1: 60/2.4 Gy). All treatments were delivered in 25 
fractions. Patients were treated according to a Phase I-II 
dose-escalation study. Toxicity was scored by CTC-AE v. 3.0 
scale.  
 
Results: Sixty-six HIR-EC patients were enrolled. The Level 1 
group included 38 patients while Level 2 group included 28 
patients. Clinico-pathological characteristics of the two 
groups are reported in Table 1. All patients completed 
radiation treatment without interruption. No differences 
were found between the 2 groups in terms of skin, 
gastrointestinal and genitourinary toxicities. 
 
 
 
With a median follow up of 20 months (range 3-48 months), 
no dose limiting toxicity was reported, therefore Level 2 was 
considered as the recommended dose. Three vaginal 
recurrences were documented at 8, 14 and 19 months after 
SIB-VMAT in Level 1 group. At two-years local control was 
90.4% (Level 1), versus 100% (Level 2), while disease free 
survival was 85.6% (Level 1) versus 93.3% (Level 2); overall 
survival was 96.2% ( Level 1) versus 100% (Level 2), 
respectively. 
 
Conclusion: To date, according with this phase I-II study 
clinical results, SIB-VMAT strategy represents the standard 
adjuvant treatment in HIR-EC at our Institution. We 
established the dose of 45Gy/1.8 Gy to pelvic nodes and 60 
Gy/2.4 Gy to the upper two thirds of vagina as the 
recommended doses for further evaluation of SIB- VMAT 
approaches in this setting. 
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Purpose or Objective: Minimisation of internal organ motion 
during pelvic radiotherapy (RT) is necessary to ensure 
accurate reproducible treatment. We analysed bladder and 
rectal filling during pelvic RT and their impact on CTV 
coverage. 
 
Material and Methods: Cone beam Computed Tomography 
scans (CBCTs) taken twice weekly during 3D conformal RT 
were retrospectively analysed for 10 cervical cancer patients. 
All patients followed the departmental guidelines; empty 
bladder then drink 4 cups of water 40 minutes before 
